<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02607657</url>
  </required_header>
  <id_info>
    <org_study_id>GDN 055/15</org_study_id>
    <nct_id>NCT02607657</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Eplerenone Tablet</brief_title>
  <official_title>Phase I Trial Comparing Eplerenone Pharmacokinetics (Tablet) in Different Dosages: 25mg, 50mg,100 mg Per Day and 100 mg (One 50 mg Tablet Every 12 Hours).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biolab Sanus Farmaceutica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biolab Sanus Farmaceutica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, open-label, randomized, parallel trial to evaluate the pharmacokinetics of&#xD;
      Eplerenone tablet at different dosages (25 mg once daily, 50 mg once daily, 100 mg (2 tablets&#xD;
      of 50 mg) once daily and 50 mg twice daily). Sample size is 96 participants (24 per treatment&#xD;
      group), male or female, aged between 18 and 50 years-old.&#xD;
&#xD;
      Primary objective is to evaluate pharmacokinetics of Eplerenone tablet at different dosages,&#xD;
      and secondary objective is to evaluate safety and tolerability of the investigational&#xD;
      product.&#xD;
&#xD;
      Study overall duration is approximately 12 weeks, including enrollment and follow-up visits.&#xD;
      Participants will be admitted for a period of 36 hours, when investigational product will be&#xD;
      administered, and blood samples, at pre-determined time periods, will be collected for&#xD;
      pharmacokinetics.&#xD;
&#xD;
      Primary endpoint is to obtain pharmacokinetics parameters. Additionally, safety will be&#xD;
      assessed by adverse events occurrence and laboratory exams evaluation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>May 2016</start_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve(0-last)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve(0-all)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve(0-inf)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (t1/2)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination rate constant (Ke)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum serum concentration (Cmax)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum (peak) plasma concentration following drug administration (tmax)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of the last measurable (positive) concentration (tlast)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the first moment of the plasma concentration-time curve extrapolated from time zero to infinity as a percentage of total AUC</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of adverse events</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Eplerenone 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eplerenone 25 mg Tablet Oral Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eplerenone 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eplerenone 50 mg Tablet Oral Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eplerenone 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eplerenone 100 mg (2 tablets of 50 mg) Tablet Oral Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eplerenone 50 mg x 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eplerenone 50 mg Tablet Oral Twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eplerenone 25 mg x 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eplerenone 25 mg Tablet Oral Twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone 25 mg</intervention_name>
    <arm_group_label>Eplerenone 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone 50 mg</intervention_name>
    <arm_group_label>Eplerenone 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone 100 mg</intervention_name>
    <arm_group_label>Eplerenone 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone 50 mg twice a day</intervention_name>
    <arm_group_label>Eplerenone 50 mg x 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone 25 mg twice a day</intervention_name>
    <arm_group_label>Eplerenone 25 mg x 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female study participants, aged between 18 and 50 years-old;&#xD;
&#xD;
          -  Healthiness, according to clinical, laboratory and electrocardiographic evaluations;&#xD;
&#xD;
          -  Ability to understand the nature and objectives of the trial, including risks and&#xD;
             adverse events; willingness to cooperate with the researcher and proceed according to&#xD;
             all study requirements, which shall be confirmed by Informed Consent Form signature.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to the investigational product (Eplerenone) or chemically&#xD;
             related compounds; history of serious adverse reactions or hypersensitivity to any&#xD;
             drug;&#xD;
&#xD;
          -  History or presence of hepatic or gastrointestinal diseases, or other condition that&#xD;
             interferes with drug absorption, distribution, excretion or metabolism;&#xD;
&#xD;
          -  Chronic therapy with any drugs, except oral contraceptives;&#xD;
&#xD;
          -  History of hepatic, kidney, lungs, gastrointestinal, epileptic, hematologic or&#xD;
             psychiatric disease; hypotension or hypertension, of any etiology, that requires&#xD;
             pharmacological treatment; history of myocardial infarction, angina and/or heart&#xD;
             failure;&#xD;
&#xD;
          -  Electrocardiographic findings that, at investigator criteria, are not recommended for&#xD;
             study participation;&#xD;
&#xD;
          -  Deviations on screening laboratory results that are considered clinically relevant by&#xD;
             the researcher, preventing the subject to participate in the trial;&#xD;
&#xD;
          -  Smoking;&#xD;
&#xD;
          -  Intake of more that 5 cups of coffee or tea per day;&#xD;
&#xD;
          -  Unusual food habits, e.g., vegetarians;&#xD;
&#xD;
          -  History of drugs and alcohol addiction or excessive alcohol consumption (&gt; 35 g/day);&#xD;
&#xD;
          -  Use of regular medications within 2 weeks prior study enrollment or use of any&#xD;
             medications within one week prior to study enrollment, except oral contraceptives or&#xD;
             cases which, based on drug's or metabolite's half-life, complete elimination can be&#xD;
             assumed;&#xD;
&#xD;
          -  Hospitalization for any reasons up to 8 weeks before trial;&#xD;
&#xD;
          -  Treatment, within 6 months before the trial, with any drugs with known and&#xD;
             well-established toxic potential to major organs;&#xD;
&#xD;
          -  Participation in any other experimental research or administration of any experimental&#xD;
             drug within 3 months before this trial;&#xD;
&#xD;
          -  Donation or loss of 450 mL or more of blood within 3 months before this trial or 3&#xD;
             donations (women)/4 donations (men) of blood within 12 months before this trial;&#xD;
&#xD;
          -  Any condition, according to investigator's best judgement, that prevents the subject&#xD;
             to participate in the trial;&#xD;
&#xD;
          -  Pregnancy, labor or miscarriage with 12 weeks before admission predicted date.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilberto De Nucci, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Galeno Desenvolvimento de Pesquisas Ltda.</affiliation>
  </overall_official>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>November 16, 2015</study_first_submitted>
  <study_first_submitted_qc>November 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2015</study_first_posted>
  <last_update_submitted>January 31, 2017</last_update_submitted>
  <last_update_submitted_qc>January 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

